Amyris, Inc. (AMRS) Cut to “Sell” at Zacks Investment Research
Amyris, Inc. (NASDAQ:AMRS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.
According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “
A number of other analysts have also weighed in on AMRS. ValuEngine lowered shares of Amyris from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. HC Wainwright set a $15.00 target price on shares of Amyris and gave the stock a “buy” rating in a report on Wednesday, June 7th. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $31.13.
Shares of Amyris (NASDAQ AMRS) traded up 0.89% on Tuesday, reaching $3.41. The company’s stock had a trading volume of 107,600 shares. Amyris has a 12 month low of $0.21 and a 12 month high of $18.15. The firm’s market cap is $67.54 million. The stock has a 50 day moving average of $3.67 and a 200-day moving average of $7.37.
Amyris (NASDAQ:AMRS) last posted its earnings results on Monday, May 15th. The biotechnology company reported ($1.95) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by $0.60. The firm had revenue of $13 million for the quarter, compared to the consensus estimate of $32.30 million. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.55) EPS. On average, analysts anticipate that Amyris will post ($3.98) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Amyris, Inc. (AMRS) Cut to “Sell” at Zacks Investment Research” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/07/11/amyris-inc-amrs-cut-to-sell-at-zacks-investment-research.html.
In related news, Director Patrick Y. Yang acquired 300,000 shares of the stock in a transaction on Friday, May 19th. The stock was acquired at an average cost of $0.29 per share, for a total transaction of $87,000.00. Following the completion of the acquisition, the director now directly owns 153,000 shares of the company’s stock, valued at approximately $44,370. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder (Mauritius) Pte Ltd Maxwell sold 652,513 shares of the firm’s stock in a transaction dated Thursday, April 20th. The stock was sold at an average price of $0.55, for a total transaction of $358,882.15. The disclosure for this sale can be found here. Company insiders own 11.30% of the company’s stock.
A hedge fund recently raised its stake in Amyris stock. Carl Domino Inc increased its stake in Amyris, Inc. (NASDAQ:AMRS) by 37.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 201,925 shares of the biotechnology company’s stock after buying an additional 54,925 shares during the period. Carl Domino Inc owned 0.07% of Amyris worth $107,000 as of its most recent SEC filing.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.